EHA 2026 Special — Full Meeting Recap

CMS just proposed closing the subcutaneous reformulation loophole in Medicare drug price negotiations — and the targets are unmistakable: Keytruda and Opdivo.

Meanwhile, Takeda beats Sotyktu head-to-head, Elicio's KRAS vaccine faces a sharp market correction, and Novartis gets its first proof-of-concept from the twelve-billion-dollar Avidity bet. Packed Monday.

Welcome to The Pharma Closeout for Monday, June 15th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Our top story — CMS published a proposed rule for an upcoming Medicare drug price negotiation cycle, and it takes direct aim at the IV-to-subcutaneous reformulation strategy. The proposal would close what CMS views as a loophole — one that currently protects medicines transitioning from intravenous to subcutaneous delivery from price negotiation under the IRA.

The two drugs in the crosshairs are obvious — Keytruda and Opdivo. Both Merck and BMS have been developing subcutaneous formulations, and the market has read those programs as partially designed to reset the product clock and sidestep IRA negotiation eligibility.

Keytruda is the world's top-selling drug. Merck has been transparent that the subcutaneous program is core to the franchise's long-term defense. If CMS's interpretation holds and subQ reformulations don't earn fresh negotiation protection, it blows a hole in the forward revenue models analysts have been building for two years.

But step back for a second — there's a legitimate patient case here. Subcutaneous delivery means reduced infusion burden, fewer clinic visits, lower system costs. Merck and BMS will argue during the comment period that this is genuine innovation being punished because it also happens to be commercially convenient.

That argument isn't baseless. But CMS is drawing a specific line — they're not saying subcutaneous delivery doesn't benefit patients. They're saying it doesn't warrant a fresh exclusion from price negotiation. That's a narrower claim, and it's considerably harder to fight.

What matters most is the downstream signal. Every company developing a subQ version of a Part B biologic as a lifecycle strategy now has to price in the risk that CMS classifies it the same way — lifecycle management, not innovation. That changes portfolio decisions being made in boardrooms this quarter.

And the timing compounds the problem. This rule targets the 2029 cycle, which means years of comment periods, potential legal challenges, maybe congressional intervention. But companies making subQ investment decisions today can't wait for that clarity. The planning uncertainty starts now.

That CMS story will dominate policy circles for weeks. But shifting to the deal and pipeline side — Takeda just reset the competitive terms in TYK2. Their inhibitor zasocitinib beat BMS's Sotyktu in a head-to-head study. Per BioPharma Dive, the results support Takeda's long-held belief in zasocitinib's superiority and could help it gain a commercial advantage over Bristol's therapy.

We've been covering Sotyktu's competitive trajectory on this show — and this is the dataset that reshapes the conversation. Head-to-head superiority is the coin of the realm for formulary positioning. Takeda just set the terms for the entire TYK2 class, and BMS's immunology franchise absorbs that hit immediately.

Novartis also got good news. Del-brax — the antisense oligonucleotide conjugate from the Avidity Biosciences acquisition — met its primary endpoint in a Phase 1/2 study targeting a muscle-wasting disease. For a twelve-billion-dollar deal, early proof-of-concept is exactly what investor day presentations get built around.

If the durability holds, sure — but Phase 1/2 to pivotal attrition in RNA therapeutics is punishing. This buys Novartis a credible answer when the acquisition price comes up on earnings calls. It doesn't retire the platform risk.

Then there's Elicio — and this one is ugly. Shares took a significant hit after ELI-002, their KRAS-targeted cancer vaccine, failed to demonstrate a meaningful benefit in recurrence or death versus observation in its Phase 2 study in adjuvant pancreatic cancer. Primary endpoint of disease-free survival missed in the intent-to-treat population. The company says it plans a Phase 3 restricted to R0 resection patients.

Heterogeneous surgical margins, aggressive biology, a tiny signal window — adjuvant pancreatic is where optimism goes to get tested. The R0 subgroup enrichment strategy is scientifically reasonable, but funding a Phase 3 after a seventy-percent equity wipeout is a different kind of challenge entirely.

A few more names to flag quickly. J&J presented data showing Talvey combined with Darzalex Faspro gaining ground in earlier-stage myeloma — the push to move bispecifics into earlier treatment lines continues. And Summit Therapeutics pulled its five-hundred-million-dollar share offering one day after announcing it, citing market conditions.

Summit is the cautionary signal worth lingering on. Ivonescimab has produced competitive data against Keytruda, and the offering still couldn't hold. The market isn't comfortable pricing China-origin oncology assets at full value — even when the clinical package says it should be.

On the smaller-cap side, Traws Pharma dropped eighteen point two percent in pre-market after a negative UK MHRA review forced deferral of its Phase 2a influenza program for tivoxavir marboxil. And Gan & Lee out of China posted simultaneous Phase 3 wins — bofanglutide in obesity, weekly insulin ludefen in diabetes. Solid data, but in a GLP-1 field this crowded, generating positive results is table stakes, not a differentiator.

On the regulatory side, two approvals from last Thursday that earned their own segment. The FDA approved AstraZeneca's Truqap — capivasertib — in combination with abiraterone and prednisone for PTEN-deficient metastatic hormone-sensitive prostate cancer. Per the FDA's announcement, this is the first and only targeted treatment approved for that biomarker-defined population.

Truqap was already on the market in breast cancer. But PTEN-deficient mHSPC is earlier-line prostate with a larger addressable population — AstraZeneca now has a precision oncology position in a space that's been almost entirely dominated by androgen-pathway agents like Xtandi and Erleada.

For listeners who live outside oncology — PTEN is a tumor suppressor, and when it's lost, AKT signaling goes into overdrive. That's the biology Truqap blocks. The clinical story is solid. The adoption story hinges on whether PTEN testing becomes routine at community urology and oncology practices — and that's the real rate-limiter for this launch.

Also from Thursday — Sanofi gained accelerated approval for Tzield, teplizumab, expanding the label to delay the decline in endogenous insulin production in children aged eight to seventeen recently diagnosed with Stage 3 type 1 diabetes. Per Sanofi, the approval was based on the PROTECT Phase 3 study and data from a substantial patient population. This came after a two-month delay.

Even modest C-peptide preservation in newly diagnosed pediatric patients tracks with meaningfully better long-term glycemic control and reduced hypoglycemia burden downstream. The T1D community has been chasing disease modification for a generation. The accelerated pathway confirms the FDA saw the unmet need clearly — the delay was regulatory mechanics, not a safety concern.

And Merck's Welireg — belzutifan — picked up an adjuvant approval in kidney cancer. We've covered the Welireg-Keytruda combination previously. This additional nod for post-surgical use extends Merck's renal cell footprint in a different direction.

HIF-2-alpha inhibition in the adjuvant setting now sits alongside checkpoint-based approaches. Whether Welireg carves a standalone role or folds into combination strategies — that answer shapes Merck's kidney cancer franchise for the next several years. One more policy note — Germany scrapped its proposed variable discount plan for pharmaceutical pricing. Details are still emerging, but any softening of European cost-containment is a quiet tailwind for companies with meaningful EU revenue exposure.

What to watch this week — SLEEP 2026 is underway in Baltimore through Wednesday. Takeda is presenting additional Phase 3 data from oveporexton in narcolepsy type 1, building the clinical narrative ahead of their NDA filing. Separately, Lilly disclosed early positive data for a new JAK inhibitor — still early stage, but worth tracking as their pipeline diversifies beyond metabolics. And Eisai secured UK government backing to expand manufacturing for Leqembi — the Alzheimer's franchise is getting real infrastructure investment behind it.

On oveporexton — with Centessa's ORX750 entering the development race, every presentation Takeda makes at SLEEP isn't just clinical storytelling. It's competitive framing. The window to define the orexin class leader is open right now, and it's narrowing fast.

That's your Pharma Closeout for Monday, June 15th. CMS taking aim at the subQ loophole with billions on the line, Takeda topping Sotyktu head-to-head, Novartis getting early proof on the Avidity bet, Elicio's seventy-percent crash, and fresh FDA approvals for Truqap and Tzield — and the week is just getting started. If this briefing saves you time, follow us on Spotify and drop a rating — it helps others in the industry find the show. We'll be back tomorrow.

Big week ahead. Get some rest tonight — see you tomorrow. ### Episode Metadata **Title:** CMS Targets SubQ Keytruda and Opdivo Loophole; Takeda Beats Sotyktu Head-to-Head; Truqap Prostate Cancer Approval | Jun 15, 2026 **Description:** CMS proposes closing Medicare negotiation loophole threatening Keytruda and Opdivo subcutaneous strategies — billions at stake. Plus Takeda's zasocitinib tops Sotyktu, Novartis validates $12B Avidity deal, Elicio's KRAS vaccine crashes, and FDA approves Truqap in prostate cancer and Tzield for pediatric T1D. **Tags:** CMS, Medicare drug price negotiation, IRA, Keytruda, pembrolizumab, Opdivo, nivolumab, subcutaneous, Merck, Bristol Myers Squibb, Takeda, zasocitinib, Sotyktu, deucravacitinib, TYK2, Novartis, Avidity Biosciences, del-brax, RNA therapeutics, Elicio Therapeutics, KRAS, cancer vaccine, ELI-002, pancreatic cancer, AstraZeneca, Truqap, capivasertib, prostate cancer, PTEN, Sanofi, Tzield, teplizumab, type 1 diabetes, Welireg, belzutifan, kidney cancer, J&J, Talvey, Darzalex Faspro, multiple myeloma, Summit Therapeutics, ivonescimab, oveporexton, narcolepsy, SLEEP 2026, Gan & Lee, bofanglutide, obesity, GLP-1, Eisai, Leqembi, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #